cis pT231-Tau Drives Neurodegeneration in Bipolar Disorder.
Bipolar Disorder
/ drug therapy
Brain
/ drug effects
Cell Survival
/ drug effects
Glycogen Synthase Kinase 3 beta
/ metabolism
Humans
Lithium Compounds
/ pharmacology
Nerve Degeneration
/ drug therapy
Neurons
/ drug effects
Psychotropic Drugs
/ pharmacology
Tauopathies
/ drug therapy
tau Proteins
/ metabolism
Bipolar disorder
GSK-3β
cis p-tau
tauopathy
Journal
ACS chemical neuroscience
ISSN: 1948-7193
Titre abrégé: ACS Chem Neurosci
Pays: United States
ID NLM: 101525337
Informations de publication
Date de publication:
20 03 2019
20 03 2019
Historique:
pubmed:
16
1
2019
medline:
24
3
2020
entrez:
16
1
2019
Statut:
ppublish
Résumé
Bipolar disorder is a complex neuropsychiatric disorder, characterized by intermittent episodes of mania and depression. Recent studies have indicated argyrophilic grains, composed of hyperphosphorylated tau, are observable in postmortem brains of bipolar patients. It remains uncertain how tau hyperphosphorylation results in neurodegeneration upon the disease. Recent studies have demonstrated that phosphorylated tau at Thr231 exists in two distinct cis and trans conformations, in which cis pT231-tau is highly neurotoxic and acts as an early driver of tauopathy in several neurodegenerative diseases. We herein employed an in vitro model, which resembles some aspects of bipolar disorder, to study the cis p-tau mediatory role. We established GSK3β overexpressing SH-SY5Y cells and examined cell viability, cis p-tau formation, and lithium effects by immunofluorescence and flow cytometry. We found an increase in cis p-tau levels as well as viability decrease in the cell model. Furthermore, we discovered that lithium treatment inhibits cis p-tau formation, resulting in diminished cell death. We also examined BD and healthy human brain samples and detected cis p-tau in the patients' brains. Our results show that tauopathy, observed in bipolar disorder, is being mediated through cis p-tau and that a conformer could be the cause of neurodegeneration upon the disease. Our findings would suggest novel therapeutic target to fight the devastating disorder.
Identifiants
pubmed: 30644730
doi: 10.1021/acschemneuro.8b00629
doi:
Substances chimiques
Lithium Compounds
0
MAPT protein, human
0
Psychotropic Drugs
0
tau Proteins
0
Glycogen Synthase Kinase 3 beta
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM